Search results for " Alan"

showing 10 items of 58 documents

PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and serine 163

1996

AbstractThe 80kDa Myristolated Alanine-Rich C-Kinase Substrate (MARCKS) in a major in vivo substrate of protein kinase C (PKC). Here we report that MARCKS is a major substrate for the lipid-activated PKC-related kinase (PRK1) in cell extracts. Furthermore, PRK1 is shown to phosphorylate MARCKS on the same sites as PKC in vitro. Thus, control of MARCKS phosphorylation on these previously identified ‘PKC’ sites may be regulated under certain circumstances by PRK as well as PKC mediated signalling pathways. The implications for MARCKS as a marker of PKC activation and as a point of signal convergence are discussed.

PhosphopeptidesMARCKSPRKRecombinant Fusion ProteinsMolecular Sequence DataBiophysicsKidneyBiochemistryCell-free systemCell LineSerineStructural BiologyProtein kinase CGeneticsAnimalsAmino Acid SequenceBinding siteMARCKSPKCPhosphorylationMyristoylated Alanine-Rich C Kinase SubstrateMolecular BiologyProtein kinase CGlutathione TransferaseBinding SitesCell-Free SystemKinaseChemistryIntracellular Signaling Peptides and ProteinsMembrane ProteinsProteinsCell BiologyHaplorhiniPeptide FragmentsBiochemistryPhosphorylationElectrophoresis Polyacrylamide GelSignal transductionSequence AnalysisSignal TransductionFEBS Letters
researchProduct

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

2021

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbi…

Research ReportMale0301 basic medicineBenzylaminesParkinson's diseaseOutcome AssessmentParkinson's diseaseComorbidityDiseaseReal-life evaluationchemistry.chemical_compound0302 clinical medicineOutcome Assessment Health Care80 and overMAO-B inhibitorAged 80 and overSafinamideeducation.field_of_studyAlanineMental DisordersParkinson DiseaseMiddle AgedMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide; Aged; Aged 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Outcome Assessment Health CareEuropeSettore MED/26 - NEUROLOGIAFemaleErratumCohort studymedicine.medical_specialtyMonoamine Oxidase InhibitorsDrug-Related Side Effects and Adverse ReactionsPopulationMEDLINE03 medical and health sciencesCellular and Molecular NeuroscienceSafinamideInternal medicinemedicineHumansAdverse effecteducationAgedRetrospective Studiesbusiness.industryMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamidemedicine.diseaseHealth Care030104 developmental biologychemistryParkinson’s diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Parkinson's Disease
researchProduct

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

2022

Background & Aims Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. Methods We profiled 2,083 serum miRNAs in a discovery cohort (183 cases with NAFLD representing the complete NAFLD spectrum and 10 population controls). miRNA libraries generated by HTG EdgeSeq were sequenced by Illumina NextSeq. Selected serum miRNAs were profiled in 372 additional cases with NAFLD and 15 population controls by quantitative reverse transcriptase PCR. Results Levels of 275 miRNAs differed between cases and population controls. Fewer differences were seen wi…

SCORING SYSTEMCPM counts per millionAUROC area under the receiver operating characteristicRC799-869AST aspartate aminotransferaseMicroRNA; Non-alcoholic fatty liver disease; Biomarker; SequencingTGF-β transforming growth factor-betaGastroenterologySTEATOHEPATITISLiver disease0302 clinical medicineFibrosismiRNA microRNAlogFC log2 fold changeFIBROSISImmunology and AllergySequencing0303 health scienceseducation.field_of_studyNAS NAFLD activity scoremedicine.diagnostic_testFatty liverGastroenterologyGTEx Genotype-Tissue ExpressionMicroRNADiseases of the digestive system. Gastroenterology3. Good healthReal-time polymerase chain reactionBiomarker MicroRNA Non-alcoholic fatty liver disease SequencingLiver biopsyACIDBiomarker (medicine)030211 gastroenterology & hepatologyLife Sciences & BiomedicineResearch ArticleEXPRESSIONmedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseNASH non-alcoholic steatohepatitisPopulationGastroenterology and HepatologySAF steatosis–activity–fibrosisVALIDATIONER endoplasmic reticulum03 medical and health sciencescDNA complementary DNAInternal medicineALT alanine aminotransferaseGastroenterologiInternal MedicinemedicineNAFL non-alcoholic fatty liverALGORITHMFIB-4 fibrosis-4education030304 developmental biologyPCA principal component analysisScience & TechnologyGastroenterology & HepatologyHepatologybusiness.industryBiomarkerFC fold changemedicine.diseaseBiomarker; MicroRNA; Non-alcoholic fatty liver disease; Sequencingdigestive system diseasesFLIP fatty liver inhibition of progressionCt cycle thresholdSteatosisqPCR quantitative PCRbusinessNon-alcoholic fatty liver disease
researchProduct

Phenol compounds for Electron Spin Resonance dosimetry of gamma and neutron beams

2014

Settore FIS/01 - Fisica SperimentaleBNCT ESR dosimetry alanine phenols Monte CarloSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

Dosimetria tramite Risonanza Elettronica di Spin (ESR) in RadioTerapia IntraOperatoria (IORT): misure di Output Factors e simulazioni Monte Carlo-GEA…

2016

La RadioTerapia IntraOperatoria (IORT) è una modalità di trattamento in cui una singola dose di radiazioni è impartita direttamente al letto tumorale o al tumore durante l'intervento chirurgico, evitando di colpire i tessuti sani circostanti. La fabbricazione di acceleratori lineari mobili per elettroni dedicati alla IORT ha permesso una grande diffusione di questa tecnica radioterapica. Lo scopo di questo lavoro è il confronto tra la risposta di dosimetri di alanina letti tramite Risonanza Elettronica di Spin (ESR) e di camere a ionizzazione Markus per le misurazioni degli Output Factors (OFs) di fasci di elettroni prodotti da un acceleratore lineare utilizzato per la IORT. Gli OFs dei fas…

Settore FIS/01 - Fisica SperimentaleIORT ESR EPR MC-Geant4 Alanina Dosimetria elettroniSettore MED/36 - Diagnostica Per Immagini E RadioterapiaSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

Characterization of the terminal column of TRIGA Mark II reactor of Mainz through of alanine pellets.

2017

We have studied the ESR response of alanine pellets with and without gadolinium exposed to the thermal column of the TRIGA Mark II research reactor at the University of Mainz (Germany). The choice of Gd as additive nucleus is due to its very high capture cross section to thermal neutrons and to the possibility for secondary particles produced after interaction with thermal neutrons of releasing their energy in the neighborhood of the reaction site. In particular, it was found that low concentration (5% by weight) of Gd brings about a neutron sensitivity enhancement of more than 10 times without heavily reducing tissue equivalence. Monte Carlo (MC) simulations of both response of alanine and…

Settore FIS/01 - Fisica SperimentaleMC simulation Alanine ESR EPR Neutron FlukaSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

ESR dosimetry with alanine added with Gadolinium in TRIGA reactor of Mainz

2014

Settore ING-IND/18 - Fisica Dei Reattori NucleariESR EPR Alanine Dosimetry TRIGASettore FIS/01 - Fisica SperimentaleSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

Caratterizzazione dosimetrica della facility a neutroni termici del reattore TRIGA di Pavia: studio della dose da fotoni mediante rivelatori ESR

2014

Settore ING-IND/18 - Fisica Dei Reattori NucleariSettore FIS/01 - Fisica SperimentaleESR alanina neutroni attivazione grafite Monte Carlo campo mistoSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

Dosimetry of Mainz reactors by means of ESR dosimetry with alanine added with gadolinium

2014

Settore ING-IND/20 - Misure E Strumentazione NucleariESR dosimetry Alanine Gadolinium NCTSettore FIS/01 - Fisica SperimentaleSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct

Characterization of the ESR response of alanine dosimeters to low-energy (1-40 keV) X-rays

2016

The aminoacid L-a-alanine has attracted considerable interest for use in radiation ESR dosimetry and has been formally accepted as a secondary standard for high-dose (kGy) and transfer dosimetry . The accuracy of the method is quite high, largely due to the low dependence of the alanine response on various irradiation parameters (photon energies above 100 keV, dose rate, temperature, etc.). Furthermore, this system presents alinear response to dose, fairly high sensitivity, tissue equivalence, absence of fading, small dimensions, ruggedn ess, and non-destructive readout. In this work, we examined the energy dependence of alanine ESR dosimeters in the low energy X-photon energy range between…

Settore ING-IND/20 - Misure E Strumentazione NucleariESR EPR Alanine Low-energy X-rays LAXSettore FIS/01 - Fisica SperimentaleSettore FIS/03 - Fisica Della MateriaSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)
researchProduct